Skip to main content
. 2017 Nov 27;15:41–50. doi: 10.1016/j.redox.2017.11.022

Fig. 5.

Fig. 5

The levels of endocannabinoids [AEA, 2-AG and NADA] and their receptors [CB1, CB2, TRPV1] and activities of enzymes degrading endocannabinoids [FAAH, MAGL] in the kidney of hypertensive rats (A-SHR; B-DOCA-salt) and hypertensive rats after the administration of URB597. A. Data points represent the mean ± SD, n = 6; (a, significantly different from WKY group, p < 0.05; b, significantly different from SHR group, p < 0.05). B. Data points represent the mean ± SD; n = 6; (a, significantly different from Wistar group, p < 0.05); b, significantly different from DOCA-salt group, p < 0.05). The results are shown in comparison to the control groups [WKY rats and Wistar rats]: endocannabinoids concentrations (AEA: 56.1 ± 2.7 pmol/g tissue for WKY rats, 43.2 ± 2.7 pmol/g tissue for Wistar rats; 2-AG: 4.53 ± 0.22 nmol/g tissue for WKY rats, 2.47 ± 0.15 nmol/g tissue for Wistar rats; NADA: 15.8 ± 0.7 pmol/g tissue for WKY rats, 16.1 ± 0.8 pmol/g tissue for Wistar rats); FAAH activity (25.0 ± 1.2 nmol m-NA/min/mg prot. for WKY rats and 22.14 ± 1.24 nmol m-NA/min/mg prot. for Wistar rats); MAGL activity (14.7 ± 0.9 nmol TNB/min/mg prot. for WKY rats and 11.5 ± 0.8 nmol TNB/min/mg prot. for Wistar rats).